Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...
“Incremental celebrates the strong results of our collaboration with Bayer and Skai,” said David Pollet, CEO of Incremental. “Integrating incrementally measurement directly into media activation ...
The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a ...
These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback